Vicore Pharma Holding AB

As of June 30, 2026, Vicore Pharma Holding AB carries a market capitalization of 319.25M, placing it among publicly traded companies globally. Its enterprise value stands at 237.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vicore Pharma Holding AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Vicore Pharma Holding AB has 281.53M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 664.22, and the price-to-book ratio stands at 4.14.

These figures are as of June 30, 2026. The EV/Sales ratio of 528.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 237.49M versus a market cap of 319.25M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vicore Pharma Holding AB maintains a current ratio of 12.68, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vicore Pharma Holding AB posted a negative return on equity (ROE) of -53.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -50.06, reflecting losses generated across the asset base. The company generates approximately 12,845.91 in revenue per employee across its workforce of 35.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vicore Pharma Holding AB recorded 23,383.18 in income tax expense. The company reported a pretax loss of -45.47M and -45.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vicore Pharma Holding AB's stock has declined approximately 8.97% over the past 52 weeks. The 50-day moving average sits at 0.90, while the 200-day moving average is 0.99.

Over the twelve months ended June 30, 2026, Vicore Pharma Holding AB generated 449,607.02 in revenue and converted that into -45.50M in net income, yielding earnings per share of -0.17. EBITDA reached -46.84M, while operating income came in at -46.84M.

These figures are as of June 30, 2026. Total book value stands at 77.07M, with working capital of 77.02M providing operational flexibility.

Vicore Pharma Holding AB produced -41.66M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -10,418.21 and net profit margin of -10,119.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.18, meaning Vicore Pharma Holding AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Vicore Pharma Holding AB's most recent stock split took place on September 17, 2024 with a 36:37 split ratio.